Literature DB >> 29756246

Ewing sarcoma of the head and neck: The Mayo Clinic experience.

Michael D Olson1, Kathryn M Van Abel1, Rebecca N Wehrs2, Joaquin J Garcia2, Eric J Moore1.   

Abstract

BACKGROUND: Treatment options of Ewing sarcoma of the head and neck include surgery, radiotherapy (RT), and chemoradiotherapy. However, local control can be challenging.
METHODS: We conducted a retrospective review of all patients with head and neck Ewing sarcoma treated from 1972 to 2015 at a single tertiary care hospital.
RESULTS: Seventeen patients met criteria (median 21 years, range 5-58 years; 5 women). Mean follow-up was 10.4 years (range 2.2-39 years). Tumors occurred commonly in the cervical spine (5/17), the skull (3/17), and the paranasal sinuses (3/17). A total of 14 of 17 patients underwent surgical resection, 9 with gross total resection. After multimodality therapy, the 5-year overall survival (OS) and recurrence-free survival (RFS) was 87% and 75%, respectively.
CONCLUSION: Combined multimodal treatment resulted in a 5-year OS and RFS of 87% and 75%, respectively. Aggressive surgical resection with adjuvant chemoradiotherapy should be considered. Although negative margin surgery is the goal, subtotal resection may be acceptable in the setting of adjuvant treatment.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; cancer; head and neck; outcome; survival

Mesh:

Year:  2018        PMID: 29756246     DOI: 10.1002/hed.25191

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

1.  Ewing Sarcoma of Larynx: A Rare Case in a 5-Year-Old Boy.

Authors:  Hamdan Ahmed Pasha; Shayan Khalid Ghaloo; Muhammad Wasif; Moghira Iqbaluddin Siddiqui; Nasir Ud Din
Journal:  Turk Arch Otorhinolaryngol       Date:  2020-03-26

2.  Larynx cancer diagnosed as Ewing Sarcoma in a 41-year-old man: A case report.

Authors:  Dima Alhomsi; Hamzeh Al Asadi; Areej Alassaf
Journal:  Ann Med Surg (Lond)       Date:  2022-09-09

Review 3.  Radiation therapy strategies for skull-base malignancies.

Authors:  J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti
Journal:  J Neurooncol       Date:  2020-08-12       Impact factor: 4.130

Review 4.  Systemic treatment for primary malignant sarcomas arising in craniofacial bones.

Authors:  Stefan S Bielack
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.